ProShare Advisors
TARS icon

ProShare Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

ProShare Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Sell
6,898
-739
-10% -$47.2K ﹤0.01% 1181
2026
Q1 		$536K Sell
7,637
-1,397
-15% -$97.6K ﹤0.01% 1020
2025
Q4 		$740K Buy
9,034
+829
+10% +$61.9K ﹤0.01% 928
2025
Q3 		$488K Sell
8,205
-1,314
-14% -$64.7K ﹤0.01% 1125
2025
Q2 		$386K Sell
9,519
-269
-3% -$12.1K ﹤0.01% 1273
2025
Q1 		$503K Sell
9,788
-2,382
-20% -$118K ﹤0.01% 1095
2024
Q4 		$674K Buy
12,170
+2,970
+32% +$135K ﹤0.01% 1098
2024
Q3 		$303K Buy
+9,200
New +$259K ﹤0.01% 1454
2024
Q2 		– Sell
-7,631
Closed -$277K – 1998
2024
Q1 		$277K Buy
+7,631
New +$224K ﹤0.01% 1473

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ProShare Advisors's TARS Position: Q2 2026 in Review

ProShare Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 9.7% in Q2 2026, selling an estimated $47.2K and leaving 6,898 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1181.

ProShare Advisors first reported a position in TARS in Q1 2024 and has held it in 9 quarters since. The position peaked at $740K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • ProShare Advisors held 6,898 shares of Tarsus Pharmaceuticals worth $434K as of Q2 2026.
  • ProShare Advisors sold 739 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $47.2K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1181 holding.
  • ProShare Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • ProShare Advisors's Tarsus Pharmaceuticals position peaked at $740K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.